Clinical Trials Using Irinotecan
- 1 February 2002
- journal article
- editorial
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 24 (2) , 84-85
- https://doi.org/10.1097/00043426-200202000-00002
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.Published by Elsevier ,2021
- Direct Translation of a Protracted Irinotecan Schedule From a Xenograft Model to a Phase I Trial in ChildrenJournal of Clinical Oncology, 1999
- Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group Study.Journal of Clinical Oncology, 1998
- DNA Topoisomerases: Essential Enzymes and Lethal TargetsAnnual Review of Pharmacology and Toxicology, 1994
- Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude miceCancer Chemotherapy and Pharmacology, 1991
- Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activityJournal of Medicinal Chemistry, 1991
- DNA topoisomerase-targeting antitumor drugs can be studied in yeast.Proceedings of the National Academy of Sciences, 1988
- Recent studies of DNA topoisomerasesBiochimica et Biophysica Acta (BBA) - Gene Structure and Expression, 1987
- DNA TOPOISOMERASESAnnual Review of Biochemistry, 1985